title: Reemergence of stroke deficits with midazolam challenge.
abstract: OBJECTIVE
  Patients who have sustained a neurological injury and then improved may experience transient reemergence of their syndromes when given benzodiazepines. As a step toward assessing whether neurotransmitter systems underlie poststroke clinical improvement, we selected midazolam, a gamma-aminobutyric acid(A) (GABA(A)) agonist, for systemic administration to measure general or stroke-specific effects in patients.
  
  
  METHODS
  Eight patients with image-verified stroke (5 with left-sided and 3 with right-sided cerebral lesions) participated. The strokes had occurred from 7 days to 6 years earlier, with patients showing clinical improvement from their initial syndromes. Each patient underwent baseline testing for motor function, aphasia, and left hemispatial neglect, after which intravenous midazolam was delivered until mild drowsiness was detected. Patients were tested during this period and again after 2 hours when sedation had dissipated.
  
  
  RESULTS
  After the administration of midazolam, the 5 patients with left hemisphere stroke demonstrated reemergence or worsening of their initial right hemiparesis and aphasia but showed no left neglect. The 3 patients with right cerebral stroke showed reemergence of left hemiparesis and left visual field neglect but no aphasia. All patients returned to baseline after 2 hours.
  
  
  CONCLUSIONS
  Under conditions of light sedation, patients whose initial stroke syndrome had substantially improved clinically showed transient reemergence of their initial focal syndrome. These data suggest a possible role for GABA(A)-mediated neurochemical mechanisms in poststroke improvement and sensitivity to medication effects.
authors.affiliation: Department of Neurology, Columbia University College of Physicians and Surgeons, Columbia-Presbyterian Medical Center, New York, NY, USA. ral22@columbia.edu
authors.forename: Ronald M
authors.initials: RM
authors.lastname: Lazar
authors.forename: Brian-Fred
authors.initials: BF
authors.lastname: Fitzsimmons
authors.forename: Randolph S
authors.initials: RS
authors.lastname: Marshall
authors.forename: Mitchell F
authors.initials: MF
authors.lastname: Berman
authors.forename: Maria A
authors.initials: MA
authors.lastname: Bustillo
authors.forename: William L
authors.initials: WL
authors.lastname: Young
authors.forename: J P
authors.initials: JP
authors.lastname: Mohr
authors.forename: Jinesh
authors.initials: J
authors.lastname: Shah
authors.forename: Julie V
authors.initials: JV
authors.lastname: Robinson
mesh_terms: D000328:Adult; D000368:Aged; D001037:Aphasia / Q000209:etiology; D005260:Female; D018757:GABA Modulators / Q000009:adverse effects*; D006801:Humans; D006993:Hypnotics and Sedatives / Q000009:adverse effects*; D008297:Male; D008874:Midazolam / Q000009:adverse effects*; D008875:Middle Aged; D010291:Paresis / Q000209:etiology; D012008:Recurrence; D020521:Stroke / Q000175:diagnosis / Q000209:etiology*; D014794:Visual Fields
chemical_list: D018757:GABA Modulators; D006993:Hypnotics and Sedatives; D008874:Midazolam